STEMI Versus NSTEMI: Clinical and Angiographic Differences

This study has been completed.

Sponsor:

Information provided by (Responsible Party):

Ferrara Liberato Aldo, Federico II University

ClinicalTrials.gov Identifier:

NCT01636427

First received: July 6, 2012

Last updated: July 17, 2012

Last verified: July 2012

History of Changes

Purpose

The purpose of this study is to assess differences in the risk profile and in the coronary angiographic presentation between STEMI and NSTEMI. Moreover possible relationship between myocardial infarction presentation and renal function will be investigated.

Condition
Acute Coronary Syndrome

Study Type:	Observational
Study Design:	Observational Model: Case-Only Time Perspective: Retrospective
Official Title:	STEMI Versus NSTEMI: a Mono Versus a Multivessel Disease?

Resource links provided by NLM:

MedlinePlus related topics: Heart Attack

U.S. FDA Resources

Further study details as provided by Federico II University:

Enrollment:	200
Study Start Date:	January 2007
Study Completion Date:	May 2012
Primary Completion Date:	May 2012 (Final data collection date for primary outcome measure)

Detailed Description:

Assessment of risk profile. Diabetes mellitus diagnosed when fasting blood glucose (FBG) was >= 126mg/dL or if patients were taking oral hypoglycaemic drugs or were on insulin treatment. Hypertension defined as blood pressure >= 140/90 mmHg or history of antihypertensive treatment. Hypercholesterolemia,adjudicated when cholesterol levels were >= 200 mg/dL or with patients on lipid lowering treatment. Hypertriglyceridemia adjudicated on fasting triglyceride levels>= 200 mg/dL or triglyceride-lowering therapy . Obesity, defined as BMI >= 30 kg/m2.

Patients with STEMI, who had not been previously treated with thrombolysis, and those who had been undergone to an unsuccessful thrombolysis, as well as patients with NSTEMI with a TIMI score> 3 who were immediately referred to the Cat Lab and whenever possible treated with PTCA and stenting of the culprit lesion. The other patients who were referred to Cat Lab within 48 hours from the beginning of chest pain, unless their general conditions did not strongly suggest to delay the procedure after 2 more days.

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Probability Sample

Study Population

Patients with acute myocardial infarction with or without ST segment elevation.

Criteria

Inclusion Criteria:

Patients admitted in the coronary care unit (CCU) of the Department of Clinical and Experimental Medicine at the Federico 2nd University Hospital;
Patient with indication to angiographic study even if not immediately;
Patients referred to CCU with the diagnosis of acute myocardial infraction (AMI), type STEMI, or NSTEMI, based on pre-admission assessment of troponin I (TpI) and myocardial band creatin kinase (CK-MB;
Diagnosis of NSTEMI/STEMI performed according to standard criteria

Exclusion criteria:

Patients who could not undergo angiographic study

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT01636427

Locations

Italy
CCU Dipartimento Assistenziale di Clinica Medica
Naples, Italy, 80131

Sponsors and Collaborators

Federico II University

Investigators

Study Director:

Giovanni de Simone, MD

Federico 2nd University of Naples

More Information

No publications provided

Responsible Party:	Ferrara Liberato Aldo, Associate Professor of Medicine, Federico II University
ClinicalTrials.gov Identifier:	NCT01636427 History of Changes
Other Study ID Numbers:	001
Study First Received:	July 6, 2012
Last Updated:	July 17, 2012
Health Authority:	Italy: Ethics Committee

Keywords provided by Federico II University:

myocardial infarction
coronary angiography
STEMI
NSTEMI

Additional relevant MeSH terms:

Acute Coronary Syndrome
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Angina Pectoris

Vascular Diseases
Chest Pain
Pain
Signs and Symptoms

ClinicalTrials.gov processed this record on June 18, 2013

To Top